EHElizabeth Helgason

Elizabeth Helgason

*This is an algorithmically generated author record based on publicly available information.

Elizabeth Helgason has a total of 115 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Constitutive protein degradation induces acute cell death via proteolysis products

    by Si-Han Chen, Sumit Prakash, Elizabeth Helgason, Caroline L. Gilchrist, Lillian R. Kenner, Rajini Srinivasan, Tim Sterne-Weiler, Marc Hafner, Robert Piskol, Erin C. Dueber, et al.

    Modulation of proteolysis is an emerging therapeutic mainstay. The clinical success of thalidomide and analogs has inspired development of rationally-designed therapeutics that repurpose endogenous degradation machinery to target pathogenic proteins. However, it is unknown whether target removal is the critical effect that drives degrader-induced efficacy. Here we report that proteasome-generated peptides actively initiate degrader-induced cell death. Utilizing BET family degraders as exemplars, we find that induced proteasomal degradation of the BRD4-long isoform (BRD4-L) generates neo-amino-terminal peptides that neutralize Inhibitor of Apoptosis (IAP) proteins to precipitate cell death. Depletion of BRD4-L paradoxically suppresses caspase activation induced by numerous BET degraders. An unbiased screen revealed that other degrader compounds, including clinical CELMoDs, rely on the same mechanism to potentiate caspase activation and apoptosis. Finally, in the context of constitutive immunoglobulin proteostasis within multiple myeloma cells, we report that therapeutic proteasomal protease inhibition alters the peptide repertoire to neutralize IAPs, thus contributing to the clinical efficacy of bortezomib. Together, these findings clarify the counterintuitive clinical benefit achieved by combining thalidomide analogs with proteasome inhibitors. Our study reveals a previously unrealized pro-apoptotic function of the peptides generated by a variety of proteolysis-modulating compounds, that provide design considerations to maximize therapeutic benefit.


  • Erratum: Phosphorylation and linear ubiquitin direct A20 inhibition of inflammation

    by Ingrid E. Wertz, Kim Newton, Dhaya Seshasayee, Saritha Kusam, Cynthia Lam, Juan Zhang, Nataliya Popovych, Elizabeth Helgason, Allyn Schoeffler, Surinder Jeet, et al.


  • Phosphorylation and linear ubiquitin direct A20 inhibition of inflammation

    by Ingrid E. Wertz, Kim Newton, Dhaya Seshasayee, Saritha Kusam, Cynthia Lam, Juan Zhang, Nataliya Popovych, Elizabeth Helgason, Allyn Schoeffler, Surinder Jeet, et al.

    Inactivation of the TNFAIP3 gene, encoding the A20 protein, is associated with critical inflammatory diseases including multiple sclerosis, rheumatoid arthritis and Crohn's disease. However, the role of A20 in attenuating inflammatory signalling is unclear owing to paradoxical in vitro and in vivo findings. Here we utilize genetically engineered mice bearing mutations in the A20 ovarian tumour (OTU)-type deubiquitinase domain or in the zinc finger-4 (ZnF4) ubiquitin-binding motif to investigate these discrepancies. We find that phosphorylation of A20 promotes cleavage of Lys63-linked polyubiquitin chains by the OTU domain and enhances ZnF4-mediated substrate ubiquitination. Additionally, levels of linear ubiquitination dictate whether A20-deficient cells die in response to tumour necrosis factor. Mechanistically, linear ubiquitin chains preserve the architecture of the TNFR1 signalling complex by blocking A20-mediated disassembly of Lys63-linked polyubiquitin scaffolds. Collectively, our studies reveal molecular mechanisms whereby A20 deubiquitinase activity and ubiquitin binding, linear ubiquitination, and cellular kinases cooperate to regulate inflammation and cell death.


  • Conformational dynamics control ubiquitin-deubiquitinase interactions and influence in vivo signaling

    by Aaron H. Phillips, Yingnan Zhang, Christian N. Cunningham, Lijuan Zhou, William F. Forrest, Peter S. Liu, Micah Steffek, James Lee, Christine Tam, Elizabeth Helgason, et al.

    Ubiquitin is a highly conserved eukaryotic protein that interacts with a diverse set of partners to act as a cellular signaling hub. Ubiquitin’s conformational flexibility has been postulated to underlie its multifaceted recognition. Here we use computational and library-based means to interrogate core mutations that modulate the conformational dynamics of human ubiquitin. These ubiquitin variants exhibit increased affinity for the USP14 deubiquitinase, with concomitantly reduced affinity for other deubiquitinases. Strikingly, the kinetics of conformational motion are dramatically slowed in these variants without a detectable change in either the ground state fold or excited state population. These variants can be ligated into substrate-linked chains in vitro and in vivo but cannot solely support growth in eukaryotic cells. Proteomic analyses reveal nearly identical interaction profiles between WT ubiquitin and the variants but identify a small subset of altered interactions. Taken together, these results show that conformational dynamics are critical for ubiquitin–deubiquitinase interactions and imply that the fine tuning of motion has played a key role in the evolution of ubiquitin as a signaling hub.


  • Erratum: Corrigendum: Conformational stabilization of ubiquitin yields potent and selective inhibitors of USP7

    by Yingnan Zhang, Lijuan Zhou, Lionel Rouge, Aaron H Phillips, Cynthia Lam, Peter Liu, Wendy Sandoval, Elizabeth Helgason, Jeremy M Murray, Ingrid E Wertz, et al.


  • Open Access

    Recent insights into the complexity of Tank‐binding kinase 1 signaling networks: The emerging role of cellular localization in the activation and substrate specificity of TBK1

    by Elizabeth Helgason, Qui T. Phung, Erin C. Dueber

    Tank‐binding kinase 1 (TBK1) serves as an important component of multiple signaling pathways. While the majority of research on TBK1 has focused on its role in innate immunity, critical functions for TBK1 in autophagy and cancer are beginning to emerge. This review highlights recent structural and biochemical studies that provide insights into the molecular mechanism of TBK1 activation and summarizes what is known to date about TBK1 substrate selection. Growing evidence suggests that both processes rely on TBK1 subcellular localization, with a variety of adaptor proteins each directing TBK1 to discrete signaling complexes for different cellular responses. Further study of TBK1‐mediated pathways will require careful consideration of TBK1 mechanisms of activation and specificity for proper dissection of these distinct signaling cascades.


  • Conformational stabilization of ubiquitin yields potent and selective inhibitors of USP7

    by Yingnan Zhang, Lijuan Zhou, Lionel Rouge, Aaron H Phillips, Cynthia Lam, Peter Liu, Wendy Sandoval, Elizabeth Helgason, Jeremy M Murray, Ingrid E Wertz, et al.

    Stabilization of ubiquitin's β1-β2 region by computational design and phage display, targeting both buried and surface residues, yields a ubiquitin variant that specifically inhibits the deubiquitinase USP7 in vitro and in cells. Protein conformation and function are often inextricably linked, such that the states a protein adopts define its enzymatic activity or its affinity for various partners. Here we combine computational design with macromolecular display to isolate functional conformations of ubiquitin that tightly bind the catalytic core of the oncogenic ubiquitin-specific protease 7 (USP7) deubiquitinase. Structural and biochemical characterization of these ubiquitin variants suggest that remodeled backbone conformations and core packing poise these molecules for stronger interactions, leading to potent and specific inhibition of enzymatic activity. A ubiquitin variant expressed in human tumor cell lines binds and inhibits endogenous USP7, thereby enhancing Mdm2 proteasomal turnover and stabilizing p53. In sum, we have developed an approach to rationally target macromolecular libraries toward the remodeling of protein conformation, shown that engineering of ubiquitin conformation can greatly increase its interaction with deubiquitinases and developed powerful tools to probe the cellular role of USP7.


  • Open Access

    Molecular basis of Tank-binding kinase 1 activation by transautophosphorylation

    by Xiaolei Ma, Elizabeth Helgason, Qui T. Phung, Clifford L. Quan, Rekha S. Iyer, Michelle W. Lee, Krista K. Bowman, Melissa A. Starovasnik, Erin C. Dueber

    Tank-binding kinase (TBK)1 plays a central role in innate immunity: it serves as an integrator of multiple signals induced by receptor-mediated pathogen detection and as a modulator of IFN levels. Efforts to better understand the biology of this key immunological factor have intensified recently as growing evidence implicates aberrant TBK1 activity in a variety of autoimmune diseases and cancers. Nevertheless, key molecular details of TBK1 regulation and substrate selection remain unanswered. Here, structures of phosphorylated and unphosphorylated human TBK1 kinase and ubiquitin-like domains, combined with biochemical studies, indicate a molecular mechanism of activation via transautophosphorylation. These TBK1 structures are consistent with the tripartite architecture observed recently for the related kinase IKKβ, but domain contributions toward target recognition appear to differ for the two enzymes. In particular, both TBK1 autoactivation and substrate specificity are likely driven by signal-dependent colocalization events.


  • Preparation of Distinct Ubiquitin Chain Reagents of High Purity and Yield

    by Ken C. Dong, Elizabeth Helgason, Christine Yu, Lilian Phu, David P. Arnott, Ivan Bosanac, Deanne M. Compaan, Oscar W. Huang, Anna V. Fedorova, Donald S. Kirkpatrick, et al.


  • Erratum: Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7

    by Ingrid E. Wertz, Saritha Kusam, Cynthia Lam, Toru Okamoto, Wendy Sandoval, Daniel J. Anderson, Elizabeth Helgason, James A. Ernst, Mike Eby, Jinfeng Liu, et al.